Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has announced that the first patient has been enrolled and has begun dosing in the company's new pancreatic cancer trial, exploring the combination of Amplia’s best-in-class FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX in newly diagnosed advanced pancreatic cancer patients.

The trial is now underway at two sites in Australia, with four additional sites in the United States expected to open shortly once final site approvals are complete.

The first stage of the study will evaluate the safety, tolerability, and pharmacokinetics of increasing daily doses of narmafotinib alongside FOLFIRINOX, administered on its standard two-week cycle. We anticipate completing the dose-escalation in Q1 2026.

Dr Chris Burns, Amplia’s CEO and Managing Director commented:

“With dosing of the first patient, this trial is now officially underway. This is an important milestone in the development of narmafotinib and we thank everyone who has worked tirelessly to get us to this point.”

First Patient Dosed In New Pancreatic Cancer Trial 